molecules-logo

Journal Browser

Journal Browser

Medical Use of Cannabis and Cannabinoids

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 6926

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, 98122 Messina, ME, Italy
Interests: clinical pharmacology; herbal medicine; nutraceuticals; cannabis; cannabinoids; pain
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

After a long history of Cannabis limited to the description of its use as a substance of abuse, in recent decades this plant and its compounds called cannabinoids have received different attention from the scientific community. In particular, cannabis and cannabinoids are raised up on the scientific scene for their usefulness in the medical field. This new interest has produced and continues to deliver a significant number of results that have been translated into clinical practice. Research on cannabis and cannabinoids is now a useful support inside the medical community in the treatment of chronic pain and, more recently, in the treatment of severe forms of childhood epilepsy (cannabidiol). Beyond the more known delta-9-tetra-hydrocannabinol and cannabidiol, the results obtained with research on other molecules present in the plant, such as cannabigerol and tetrahydrocannabiverine, are encouraging and indicate that Cannabis can still be a source of interesting scientific discoveries that can be translated into useful applications in the field of medicine. 

This Special Issue welcomes the submission of unpublished manuscripts (original research papers or review articles) on all aspects of the medical use of cannabis and cannabinoids involved.

Prof. Dr. Gioacchino Calapai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Cannabis sativa
  • Cannabis
  • Cannabinoids
  • CB1
  • CB2
  • Medical use

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

17 pages, 2580 KiB  
Review
Safety of Medical Cannabis in Neuropathic Chronic Pain Management
by Alessandra Bennici, Carmen Mannucci, Fabrizio Calapai, Luigi Cardia, Ilaria Ammendolia, Sebastiano Gangemi, Gioacchino Calapai and Daniel Griscti Soler
Molecules 2021, 26(20), 6257; https://doi.org/10.3390/molecules26206257 - 16 Oct 2021
Cited by 21 | Viewed by 6347
Abstract
Products derived from the plant Cannabis sativa are widely appreciated for their analgesic properties and are employed for the treatment of chronic neuropathic pain. Only nabiximols, a product composed of two extracts containing similar percentages of the two cannabinoids cannabidiol and delta-9-tetrahydrocannabinol, is [...] Read more.
Products derived from the plant Cannabis sativa are widely appreciated for their analgesic properties and are employed for the treatment of chronic neuropathic pain. Only nabiximols, a product composed of two extracts containing similar percentages of the two cannabinoids cannabidiol and delta-9-tetrahydrocannabinol, is approved by regulatory authorities for neuropathic pain and spasticity due to multiple sclerosis in many European countries and Canada. It is also included in pharmacovigilance systems monitoring the occurrence of adverse drug reactions. However, it is not the same for the great variety of other cannabis preparations widely used for medical purposes. This creates a situation characterized by insufficient knowledge of the safety of cannabis preparations and the impossibility of establishing a correct risk–benefit profile for their medical use in the treatment of chronic neuropathic pain. With the aim to explore this issue more deeply, we collected data on adverse reactions from published clinical studies reporting the use of cannabis for neuropathic relief. Full article
(This article belongs to the Special Issue Medical Use of Cannabis and Cannabinoids)
Show Figures

Figure 1

Back to TopTop